Startup Pinnacle Medicines is developing peptide drugs with the same efficacy as biologic medicines and the dosing convenience of oral small molecules. The lead program of OrbiMed-incubated Pinnacle is on track to enter the clinic in asthma and chronic obstructive pulmonary disease.
The post Pinnacle Medicines Adds $89M for Oral Peptides With Properties of Injectable Biologics appeared first on MedCity News.
